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SUMMARY
The human body’s general inflammatory response, orchestrated by molecular signals, functions
in both adaptive and innate immunity, allowing the body to isolate injurious agents. Unchecked,
it can evolve into storms where the signals for adaptive and innate immunity are produced in
excessive amounts, resulting in a severe inflammatory response. It is critical to understand how
these signals are induced and ultimately stopped, since too little or too much of an inflammatory
response can lead to diseased states. In light of recent events, it is imperative to understand the
key inflammatory response elements that appear to be the source of more severe ailments
resulting from a SARS-CoV-2 viral infection, known as Covid-19, to mitigate the effects of the
pandemic. The more severe cases of Covid-19 are characterized by a severe inflammatory
response resulting in tissue damage. Two possible culprits are a bradykinin storm or an
interleukin-6 (IL-6)-mediated cytokine storm, where in both systems, the release of certain
signals subsequently signal the production of even more of the same signal, resulting in a vicious
positive feedback loop (2, 10, 21). Recent evidence points towards bradykinin, a substrate of the
angiotensin-converting enzyme (ACE), as being responsible for the severe Covid-19
inflammatory response (1-4). This is because the SARS-CoV-2 virus targets ACE, a cell surface
protein directly involved in bradykinin metabolism and the renin-angiotensin system (10).
Bradykinin storm symptoms align similarly with what is seen in Covid-19 infection (3). I
hypothesize based on SARS-CoV-2’s direct interference with the renin-angiotensin
pathway, that it is the bradykinin storm responsible for the more severe complications of
Covid-19, as opposed to a cytokine storm. However, isolating one storm over the other has
yet to be tested. I aim to determine which storm induces the severe responses of Covid-19,
such as tissue damage, hypoxemia, and fluid buildup. To determine the nature of the storm
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that induces the severe responses of Covid-19, I will test how Actemra, a cytokine IL-6 inhibitor,
and icatibant, a bradykinin inhibitor, prevent such responses in a Covid-19 mouse model. The
possibility exists that the systems work together, where one system induces the other or they act
in parallel.

Specific Aim 1: Is the bradykinin storm solely responsible for the severe symptoms
resulting from the overactive inflammatory responses in Covid-19 patients?
I will have four groups of humanized transgenic mouse K18-hACE2, which expresses the
same human ACE receptor previously used when studying the first SARS outbreak in 2003 (5). I
will infect the transgenic mouse with SARS-CoV-2, which will allow us to observe the
symptoms found in patients with chronic infections, without using human patients. Previous
studies have indicated that this mutated mice exhibits similar symptoms as humans upon
infection (5). I will study four groups of these mice: group 1 treated with the bradykinin
inhibitor; group 2 treated with the IL-6 inhibitor; group 3 given both inhibitors to test whether
both pathways play a role; and group 4 is the control. I will be testing which drug will be more
effective in treating the symptoms observed in the groups.
Specific Aim 2: Does a bradykinin storm lead to a cytokine storm, or the opposite, if both
systems play a role?
If group 3 of the K18-hACE2 mice from Aim 1 have alleviated symptoms due to the
presence of both inhibitors, then bradykinin and cytokines may induce the other or work in
parallel. To test this, I will create a loss-of-function mutation and a gain-of-function mutation in
K18-hACE2 mice. Based on bradykinin’s direct interaction with the ACE protein, I expect that a
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bradykinin storm will be responsible for triggering a cytokine storm, if what is observed in the
third group of mice holds to be true.

BACKGROUND AND SIGNIFICANCE
Bradykinin and Renin-Angiotensin System
Bradykinin (BK) is a nonapeptide produced from a decapeptide and is normally found in
the blood in its inactive form (6). BK is an extremely potent vasodilator and is a physiological
mediator of anaphylaxis, which is caused by mast cell activation and release, following the
binding of specific antigens to IgE antibodies on mast cell membranes (6). BK acts with the
renin-angiotensin system to regulate blood flow (34).
The renin-angiotensin system functions in clearing renal waste and maintaining blood
flow. A reduction in blood flow will release renin, which converts the hormone angiotensinogen
into angiotensin 1, which in turn will be converted into the active angiotensin 2 (Fig 1; ref. 35).
Angiotensin 2 acts on the peripheral arteries of the body to increase blood pressure via
vasoconstriction and signals the adrenal glands to produce aldosterone and promote reabsorption
of salts and water by the kidneys (Fig 1; ref. 35).
The counter to this system involves the membrane protein ACE2. ACE2 is a functional
receptor expressed in the lungs, kidney, heart, and intestines (12). It consists of an extracellular
N-terminal peptidase domain and a C-terminal transmembrane anchor (12). The active form of
ACE2 is induced by the enzyme sheddase, which cleaves the external domain of the ACE2
protein (Fig 2). This cleaved ACE2 is released into the bloodstream, where it interacts with
angiotensin 2, a vasoconstrictor (Fig 2; ref. 35). The conversion of angiotensin 2 to angiotensin
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1-7, a powerful vasodilator and antioxidant, by ACE2 effectively inactivates angiotensin 2 and
lowers blood pressure and aldosterone, antagonizing the renin-angiotensin system (Fig 2; ref.
35).

Fig 1. The renin-angiotensin system.
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Fig 2. The activity of sheddase counters the activity of the renin-angiotensin system.

The bradykinin storm occurs when ACE2 is depleted, since this leads to increased levels
of DABK, a bioactive metabolite of BK, which is associated with lung injury and inflammation
(10). Depletion of ACE2 causes constant vasoconstriction that is induced by the reninangiotensin system, which can lead to tissue damage (9, 10). High levels of DABK trigger
endoplasmic reticulum stress, mitochondrial death signaling, ACE2 downregulation,
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upregulation of proinflammatory genes, all of which guide the cell into apoptosis (10). Cell
injury further increases the severity of the response, as it upregulates the BK B1 receptor,
amplifying the DABK-mediated inflammation and damage (10, 18). This results in a positive
feedback loop of inflammation and injury.

Cytokine Storm
Cytokines are a variety of proteins that are secreted by cells as signals that act on many
systems of the body (17). They have autocrine, paracrine, and endocrine activities and induce a
variety of responses (17). There are five major types of cytokines: interferons, which regulate
innate immunity and activate antiviral properties; interleukins, which affect the growth and
differentiation of leukocytes and can be proinflammatory; chemokines that control chemotaxis
and leukocyte recruitment; colony-stimulating factors, which stimulate hematopoietic progenitor
cell proliferation and differentiation; and lastly, tumor necrosis factors, which activate cytotoxic
T lymphocytes (17). Cytokines alone are rather potent: when the signaling system produces too
many, it can result in a positive feedback loop and a severe inflammatory response. This process
is referred to as a cytokine storm (17). Inflammation begins at a local site and spreads throughout
the body through the circulatory system. When localized within a tissue, vascular leukocytes and
plasma proteins reach the extra-vascular site of injury and generate pain (17). Severe
inflammation damages tissue structures and the scar tissues that form can result in organ
dysfunction and long-term damage (17). In humans, a cytokine storm can result in collagen
deposition in the lungs, which damage the lungs and lead to co-morbidities such as opportunistic
bacterial, fungal, or viral infections and sepsis (17). Interleukin-1β (IL-1β) and interleukin-8 (IL8) initiate the storm, appearing within the first few hours of a response and are followed by a
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sustained increase in interleukin-6 (IL-6) (17). Sustained levels of IL-6 increase the severity of
the storm (17).

The SARS-CoV-2 Viral infection and Covid-19
SARS-CoV-2 is a newly emerged pathogen first identified in Wuhan, Hubei Province,
China, in December 2019, which causes the disease Covid-19. Initially diagnosed as a viralinduced pneumonia by clinicians, SARS-CoV-2 was eventually isolated in bronchoalveolar
lavage fluid from Covid patients (2, 4, 12). Coronaviruses are serologically divided into four
subfamilies: α, β, γ, and δ-coronaviruses, where the first two groups infect humans. Covid-19
was identified to be from the β coronavirus family (11). SARS-CoV-2 is a positive-sense, singlestranded RNA with a genome size of 29.9 kb and a nucleocapsid that is composed of genomic
RNA and phosphorylated nucleocapsid proteins (12, 13). The genome is encapsulated by a
phospholipid bilayer with two different spike proteins protruding from the membrane: a spike
glycoprotein trimer common to all coronaviruses, and the hemagglutinin-esterase. SARS-CoV-2
targets the human ACE2, the functional receptor in the renin-angiotensin system. The spike
proteins of SARS-CoV-2 bind to ACE2, which results in the shedding of the S1 subunit of the
spike protein and a conformational change in the S2 subunit (12). This allows membrane fusion
with the host cell (12). SARS-CoV-2 causes the disease Covid-19, which results in a respiratory
illness characterized by fever, cough, myalgia, sputum production, heloptysis, diarrhea and
dyspnea (14). Severe cases of Covid-19 can result in comorbidities like sepsis, hypoxemia,
pneumonia, fluid in the lungs, and tissue damage (7, 15, 16).
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The reason behind the severe symptoms of Covid-19 is hypothesized to be the direct
result of a cytokine storm (2, 19, 24). The exact mechanisms of how a cytokine storm results in
acute lung injury and acute respiratory distress syndrome in Covid-19 patients are unknown (25).
In an analysis of 82 cases, 68 of which resulted in death, significantly higher levels of IL-6 were
detected in more severe cases than in mild cases (26). Considering that sustained levels of IL-6
are associated with increasing severity of cytokine storms, this lends to the possibility that a
cytokine storm is responsible for the severe cases of Covid-19.
Very recently, however, bradykinin storms are gaining attention and are also considered a
possibility, since SARS-CoV-2 targets the ACE2 protein and depletes it (10). Binding of Covid19 to the ACE2 protein prevents sheddase from binding and directly interferes with the reninangiotensin system (10). This interference triggers increased levels of DABK, which leads to a
bradykinin storm (10). The bradykinin storm is also more associated with fluid in the lungs than
is the case for a cytokine storm (10). This direct interference is what has led many, including
myself, to believe that a bradykinin storm is responsible for the severity of chronic SARS-CoV-2
infections (10).
It is imperative that we understand how SARS-CoV-2 interacts with the body and the
mechanism by which it causes such severe damage and respiratory distress as we are still
suffering through the Covid-19 pandemic. Understanding the mechanisms by which the two
storms, bradykinin and cytokine, affect the body, separate or together, is crucial to mitigating the
pandemic’s effect, saving lives, and producing effective treatments that we presently lack.
Despite this being the first coronavirus pandemic, severe epidemics of the same family have
existed before and will likely exist again, especially with the emergence of new and infectious
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variants of SARS-CoV-2 (27). By understanding the mechanisms through which the virus acts
on our physiology, we may be able to reduce the severity of future outbreaks and save lives.

APPROACH
Specific Aim 1: Is the bradykinin storm solely responsible for the severe symptoms resulting
from the overactive inflammatory responses in Covid-19 patients?
A.

Rationale

SARS-CoV-2 targets the cell surface protein ACE2, inhibiting the action of the enzyme
sheddase and leading to increased DABK levels (10). An increase in DABK can lead to a
bradykinin storm, thus the severe inflammatory responses in Covid-19 patients (10). However,
the possibility exists that a cytokine storm is the cause for the severity of Covid-19. Inhibitors of
IL-6, such as Actemra, have already been approved for distribution to patients with Covid-19 (8).

B.

Research Design: Viral Infection and Mice

To test the cause behind the severe Covid-19 response, I plan to use the K18-hACE2
transgenic mouse, which expresses the human ACE2 receptor, as well as the hallmark features of
the human disease (28, 29). The mice are highly susceptible to SARS-CoV-1 infection and
display symptoms characteristic of Covid-19 (28). Infection of SARS-CoV-1 in K18-hACE2
leads to a 14-day infection period, where the infection is almost exclusively localized to the
lungs (28). I chose this model due to these similarities between SARS-CoV-1, for which the
model was initially created, and SARS-CoV-2, in addition to its expression of ACE2. Previous
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studies on this mouse model showed that a cytokine storm induced the inflammatory response
observed in the lungs and the spleen of the mice infected with SARS-CoV-2 (29).
I will have four groups of specific-pathogen free, 4-to-5-week-old K18-hACE2 mice,
where each group will have 20 mice—ten male and ten females. Three of the four groups will be
infected with SARS-CoV-2 intranasally with 105 PFU (plaque forming units) of SARS-CoV-2 in
a final volume of 50 µl following sedation. The final group, the control, will be mock-infected to
ensure equal handling. I chose this concentration based on a previous study that observed an
inflammatory response at this concentration (29). To prevent cross-group coprophagy and crossinfection, the groups will not interact with one another before, during, and after treatment is
administered and will be given sterile water and the same type of food. After viral infection, the
mice will be monitored daily for morbidity (body weight) and mortality, as well as subjected to a
blood test every two days. Blood IL-6 levels and blood plasma BK levels will be analyzed and
recorded for all mice.
When the mice begin to exhibit an inflammatory response, the drug treatments will begin.
The first group will be given the IL-6 inhibitor Actemra, which is approved for use against a
cytokine storm in Covid-19 patients, over a 14-day period. All symptoms will be recorded, as
well as any changes, in addition to measurements of IL-6 and BK levels. The second group will
be given icatibant, an FDA-approved BK inhibitor, over a 14-day period, where again all
symptoms and changes will be recorded, as well as IL-6 and BK levels. These two groups will
test if one storm is more responsible than the other for the severe Covid-19 responses; if
treatment with only a BK inhibitor or only an IL-6 inhibitor proves to be effective in mitigating
the inflammatory response, I can conclude that the corresponding storm is responsible for the
response. The third group will also test the possibility that both storms are present at the same
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time. When the third group of mice begin to exhibit an inflammatory response, they will be given
both Actemra and icatibant over a 14-day period; the BK and IL-6 levels and symptoms will be
recorded, just as in other groups. The final group is the control, where no treatment will be
administered except for a mock infection.

C.

Potential Outcomes, Caveats, and Alternative Methods

Cytokine levels have already been observed to be increased in Covid-19 patients. Thus,
whether IL-6 contributes or does not contribute to the inflammatory response is not necessarily
the question. However, the cause for the severe inflammatory responses of Covid-19 remain
unclear. If cytokines are solely responsible for the severe inflammatory response, I would expect
a decrease in IL-6 levels in the first and third group of mice, in addition to reduction of the
severity of their symptoms. The same principle applies if a bradykinin storm is solely
responsible: I will only observe an alleviation in the symptoms of the second and third group of
animals and a decrease in BK levels. However, because the possibility exists that both could be
present and potentially acting on one another, I created a third group of mice. If this is the case
what I expect to observe is little to no change in the symptoms of the mice in groups one and two
respectively, and an alleviation of symptoms in the third group.
However, I may also observe a mitigation of the inflammatory response with each single
drug treatment, where a bradykinin storm might lead to a cytokine storm, or vice versa. I will
address this outcome in Specific Aim 2.
There are also some potential concerns. The possibility exists that the mice do not
generate a storm-like response or do not respond well to the drugs. If the response generated by
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SARS-CoV-2 infection is too strong or does not appear at all, I will decrease or increase the
concentration of SARS-CoV-2, respectively. According to previous studies, the inflammatory
response necessary for this study can be produced (29). Thus, if this problem arises, changing the
viral load should address this issue (29). If the mice do not respond well to one or both drugs, or
if the drugs do not do what they are expected to do, I will find a different IL-6 inhibitor or a
different BK inhibitor. Ideally, I can use a greater number of mice, or a quantity closer to 30-40
per group. However, the mice are in low supply and, because of the pandemic, are in high
demand (28, 29).

Specific Aim 2: Does a bradykinin storm lead to a cytokine storm, or the opposite, if both
systems play a role?
A.

Rationale:

Understanding how one pathway functions and potentially affects the other is imperative
in understanding the roles of BK and IL-6 in generating the observed inflammatory response in
Covid-19 patients. To test this, single mutations and double mutations will be created and the
resulting phenotypes will be compared post infection.

B.

Research Design

First I will create single mutants using genetic knockouts. These will be a series of
mutations to create gain-of-function mutations and loss-of-function mutations. To create a BK
loss of function, I will delete the BK gene using a CRISPR/Cas9 knockout plasmid that targets
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the BK gene, so that cells can no longer express BK (30, 36). To generate a BK gain of function,
I will induce a bradykinin storm, which can occur when ACE2 is depleted in an organism, since
it leads to increased levels of DABK (10). Thus, I will use ACE2-deficient mice, the same
variety used in previous studies of the renin-angiotensin system, to induce overexpression of BK
(31). Both loss-of-function and gain-of-function models will be bred for homozygosity.
To create an IL-6 loss-of-function mutation, I will use the transgenic mouse IL6-DIOKO, which has lost IL-6 expression (33). To induce an IL-6 gain-of-function, I will use a
transgenic mouse that use the Clara cell 10-kDa promoter to drive overexpression of IL-6 (32). I
will also create double mutants, combining loss-of-function and gain-of-function mutations in
BK and IL-6 in these mouse strains.
I will then infect the mutant mouse strains with SARS-CoV-2 and record symptoms
daily, using the same procedure as described in the first specific aim.

C.

Potential Outcomes, Caveats, and Alternative Methods.

A major concern rests with the BK loss-of-function mutant or in the double mutants, for
example, the mutants expressing loss-of-function mutations in both IL-6 and BK. There is a
possibility that these mice may not be viable or may present a multitude of health issues and
might not survive SARS-CoV-2 infection long enough for me to observe responses. The same
could be true for the mutants expressing both gain-of-function mutations. If this were to happen,
I would have to find a way to create a reduction-of-function mutation, as opposed to a complete
loss-of-function mutation, such as introducing siRNAs against BK to create a reduction-offunction mutation without completely deleting the gene (37).
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Another potential concern is that ACE2-depleted mice might not cause a BK storm. A
reduction of ACE2 leads to increased DABK, but there is no guarantee that this alone will cause
a BK storm in transgenic mice. If this were to happen, an alternative approach would be to
couple this mutation with another mutation that causes overexpression of BK receptors (38, 39).
If the phenotype of the double mutants matches one of the single mutations, I can
conclude the epistasis between the pathways. If the phenotype of the double mutants does not
match any of the single mutants, then the two pathways might work in parallel. While the exact
mechanism might not be known on how these two pathways act in parallel, my proposed
experiments will provide insight on the interaction between the two pathways.

CONCLUSION
As of July 2021, almost 200 million people have contracted Covid-19 and over 4 million have
died (40). While the fatality rate has certainly decreased over time, the effects of the pandemic
changed daily life drastically for many (41). The long-term effects of the disease remain largely
unknown because of its recent occurrence, and it becomes increasingly imperative that the
mechanisms of human immunity are understood to prevent the deaths of millions. This was not
the first pandemic that we have encountered and will certainly not be the last. Understanding the
body’s adaptive and innate immune responses will allow us to create treatments for future
epidemics and pandemics. This may also allow us to predict the way future strains might affect
our bodies before they bloom into devastating pandemics. A further understanding of how
bradykinins and cytokines function together to create the inflammatory responses observed as a
result of SARS-CoV-2 infection and other diseases is also absolutely critical in developing
effective treatments for these diseases. Knowing how both pathways potentially interact with one
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another would allow us to prevent prolonged tissue damage in the instance of a bradykinin or a
cytokine storm. Besides Covid-19, my study should also yield insight into the study of other
diseases that result in severe inflammatory responses caused by these molecular signals.
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